Mitsubishi Tanabe Pharma America Announces Long-Term Findings from Post-Marketing Safety Study of RADICAVA® (edaravone)

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced findings from an analysis of post-marketing safety data evaluating RADICAVA® (edaravone) in a real-world setting during the first three years of availability in the United States (U.S.) for the treatment of amyotrophic lateral sclerosis (ALS). RADICAVA maintained a similar safety profile as seen in clinical trials, with no new safety…

Read the full article here

Source: finance.yahoo.com

Categories: Latest Headlines, Rare Disease

Tweets with this article

ALS Advocacy

Mitsubishi Tanabe Pharma America Announces Long-Term Findings from Post-Marketing Safety Study of RADICAVA® (edaravone) https://t.co/UHwbvTa4E8 via @YahooFinance

Califf’s long day on Capitol Hill

Democrats and Republicans pressed FDA Commissioner Robert Califf on the FDA’s slow pace.

ALS Advocacy April 20, 2024

AI investments will help chip sector to recover: Analyst

The semiconductor sector is undergoing a correction as interest rate cut expectations dwindle, prompting concerns about the impact on these high-growth, technology-driven stocks. Wedbush Enterprise…

conciergedoc April 19, 2024

Enhanced Levels of Fractalkine and HSP60 in Cerebrospinal Fluid of Sporadic Amyotrophic Lateral Sclerosis Patients – PubMed

Amyotrophic Lateral Sclerosis (ALS) is a multifactorial neurodegenerative disorder with a significant contribution of non-cell autonomous mechanisms to motor neuronal degeneration. Amongst a plethora of…

ALS Advocacy April 19, 2024

Related Articles